252 related articles for article (PubMed ID: 19017757)
21. Diagnostic significance of parafibromin expression in parathyroid carcinoma.
Gao Y; Wang P; Lu J; Pan B; Guo D; Zhang Z; Wang A; Zhang M; Sun J; Wang W; Liang Z
Hum Pathol; 2022 Sep; 127():28-38. PubMed ID: 35654240
[TBL] [Abstract][Full Text] [Related]
22. Challenging lesions in the differential diagnosis of endocrine tumors: parathyroid carcinoma.
Delellis RA
Endocr Pathol; 2008; 19(4):221-5. PubMed ID: 19058032
[TBL] [Abstract][Full Text] [Related]
23. Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center.
Juhlin CC; Nilsson IL; Lagerstedt-Robinson K; Stenman A; Bränström R; Tham E; Höög A
Mod Pathol; 2019 Jul; 32(8):1082-1094. PubMed ID: 30923346
[TBL] [Abstract][Full Text] [Related]
24. Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas.
Juhlin CC; Nilsson IL; Johansson K; Haglund F; Villablanca A; Höög A; Larsson C
Endocr Pathol; 2010 Sep; 21(3):166-77. PubMed ID: 20473645
[TBL] [Abstract][Full Text] [Related]
25. HRPT2 gene analysis and the diagnosis of parathyroid carcinoma.
Cetani F; Pardi E; Banti C; Borsari S; Ambrogini E; Vignali E; Cianferotti L; Viccica G; Pinchera A; Marcocci C
Expert Rev Endocrinol Metab; 2008 May; 3(3):377-389. PubMed ID: 30754207
[TBL] [Abstract][Full Text] [Related]
26. A Young Male with Parafibromin-Deficient Parathyroid Carcinoma Due to a Rare Germline HRPT2/CDC73 Mutation.
Kapur A; Singh N; Mete O; Hegele RA; Fantus IG
Endocr Pathol; 2018 Dec; 29(4):374-379. PubMed ID: 30361844
[TBL] [Abstract][Full Text] [Related]
27. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma.
Shattuck TM; Välimäki S; Obara T; Gaz RD; Clark OH; Shoback D; Wierman ME; Tojo K; Robbins CM; Carpten JD; Farnebo LO; Larsson C; Arnold A
N Engl J Med; 2003 Oct; 349(18):1722-9. PubMed ID: 14585940
[TBL] [Abstract][Full Text] [Related]
28. Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors.
Wang O; Wang CY; Shi J; Nie M; Xia WB; Li M; Jiang Y; Guan H; Meng XW; Xing XP
Chin Med J (Engl); 2012 Aug; 125(16):2895-901. PubMed ID: 22932087
[TBL] [Abstract][Full Text] [Related]
29. Role of Histological Criteria and Immunohistochemical Markers in Predicting Risk of Malignancy in Parathyroid Neoplasms.
Kumari N; Chaudhary N; Pradhan R; Agarwal A; Krishnani N
Endocr Pathol; 2016 Jun; 27(2):87-96. PubMed ID: 26984237
[TBL] [Abstract][Full Text] [Related]
30. Parathyroid Carcinoma: Diagnosis and Clinical Implications.
Duan K; Mete Ö
Turk Patoloji Derg; 2015; 31 Suppl 1():80-97. PubMed ID: 26177319
[TBL] [Abstract][Full Text] [Related]
31. Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment.
Cetani F; Pardi E; Ambrogini E; Banti C; Viacava P; Borsari S; Bilezikian JP; Pinchera A; Marcocci C
J Endocrinol Invest; 2008 Oct; 31(10):900-4. PubMed ID: 19092296
[TBL] [Abstract][Full Text] [Related]
32. Parafibromin as a diagnostic instrument for parathyroid carcinoma-lone ranger or part of the posse?
Juhlin CC; Höög A
Int J Endocrinol; 2010; 2010():324964. PubMed ID: 21197463
[TBL] [Abstract][Full Text] [Related]
33. Parafibromin, APC, and MIB-1 Are Useful Markers for Distinguishing Parathyroid Carcinomas From Adenomas.
Hosny Mohammed K; Siddiqui MT; Willis BC; Zaharieva Tsvetkova D; Mohamed A; Patel S; Sharma J; Weber C; Cohen C
Appl Immunohistochem Mol Morphol; 2017; 25(10):731-735. PubMed ID: 27490759
[TBL] [Abstract][Full Text] [Related]
34. Insights into Hyperparathyroidism-Jaw Tumour Syndrome: From Endocrine Acumen to the Spectrum of
Gheorghe AM; Sima OC; Florescu AF; Ciuche A; Nistor C; Sandru F; Carsote M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396977
[TBL] [Abstract][Full Text] [Related]
35. Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation.
Kelly TG; Shattuck TM; Reyes-Mugica M; Stewart AF; Simonds WF; Udelsman R; Arnold A; Carpenter TO
J Bone Miner Res; 2006 Oct; 21(10):1666-71. PubMed ID: 16995822
[TBL] [Abstract][Full Text] [Related]
36. Negative parafibromin staining predicts malignant behavior in atypical parathyroid adenomas.
Kruijff S; Sidhu SB; Sywak MS; Gill AJ; Delbridge LW
Ann Surg Oncol; 2014 Feb; 21(2):426-33. PubMed ID: 24081804
[TBL] [Abstract][Full Text] [Related]
37. Tumor suppressor gene mutation in a patient with a history of hyperparathyroidism-jaw tumor syndrome and healed generalized osteitis fibrosa cystica: a case report and genetic pathophysiology review.
Parfitt J; Harris M; Wright JM; Kalamchi S
J Oral Maxillofac Surg; 2015 Jan; 73(1):194.e1-9. PubMed ID: 25511968
[TBL] [Abstract][Full Text] [Related]
38. Loss of expression for the Wnt pathway components adenomatous polyposis coli and glycogen synthase kinase 3-beta in parathyroid carcinomas.
Juhlin CC; Haglund F; Villablanca A; Forsberg L; Sandelin K; Bränström R; Larsson C; Höög A
Int J Oncol; 2009 Feb; 34(2):481-92. PubMed ID: 19148484
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic and prognostic implications of parafibromin immunohistochemistry in parathyroid carcinomaT.
Pyo JS; Cho WJ
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30926677
[TBL] [Abstract][Full Text] [Related]
40. Parafibromin expression, single-gland involvement, and limited parathyroidectomy in familial isolated hyperparathyroidism.
Iacobone M; Barzon L; Porzionato A; Masi G; Macchi V; Marino F; Viel G; Favia G
Surgery; 2007 Dec; 142(6):984-91; discussion 984-91. PubMed ID: 18063086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
